IBT takes profits on Nektar, buys Array SV Health-managed International Biotech Trust (IBT) saw a 2.2% fall in NAV in February, beating the 2.6% decline reported for the sterling-adjusted value of the benchmark Nasdaq biotechnology index by a small margin, one of only a handful of sector specialist trusts to do so. The main positive […]
Biotech Growth’s big-bio focus a cause of underperformance in February OrbiMed-managed Biotech Growth Trust (BIOG) saw a 3.9% fall in its NAV in February, under-performing against a 2.6% decline in the sterling-denominated value of the benchmark NASDAQ Biotechnology Index. The value of investments held by the trust were hit in the market wide sell-off in […]
Regional REIT NAV falls on dilutive share issuance and debt refinancing costs – Regional REIT has published its results for the year ended 31 December 2017. Its EPRA NAV fell to 105.9 from 106.9p, predominately due to the issuance of two tranches of new equity and debt refinancing costs. EPRA EPS rose to 8.1p from 7.7p. They declared dividends […]
India Capital Growth shareholders made 59% in 2017 – India Capital Growth had a great 2017, returning 59% to shareholders and delivering a 42.3% return on its NAV. The NAV just failed to beat its notional benchmark, the BSE Midcap, which returned 45.3%. The 3% underperformance arose in December when three significant portfolio holdings corrected […]
JPMorgan American bailed out by small caps – The year to 31st December 2017 was another positive one for investors in US equities, as the S&P 500 Index on a total return basis rose a further 21.5% for US investors, or 11.0% for UK investors once the effect of sterling’s appreciation against the US dollar […]
WPCT gets boost from Prothena-Celgene deal Shares in Woodford Patient Capital Trust (WPCT) have risen by almost 10% this morning to 78p on news of a partnership announced after US markets closed last night between its largest investee company, Prothena (NASDAQ:PRTA) and Celgene (NASDAQ:CELG). The partnership will develop new therapies for neurodegenerative disease, including Alzheimer’s, and […]
JPMorgan US Smaller Companies beats benchmark helped by stocks such as Grubhub – JPMorgan US Smaller Companies says that, in 2017, its share price rose by 7.7% and the NAV increased 6.3%. Good stock selection has resulted in outperformance of its benchmark index, the Russell 2000 which rose by 4.5% in sterling terms. The board is recommending a […]
Dunedin Enterprise shareholders made 74% in 2017 – [shame it is winding up!] Dunedin Enterprise made an NAV return of 23.9% over 2017. Shareholders did even better, with a total return to shareholders of 74.8%. This was boosted by a return of capital to shareholders of 100p per share and the payment of dividends of 31p. The net asset value decreased […]
Impact Healthcare REIT delivers small NAV uplift – Impact Healthcare REIT has published results for the period ended 31 December 2017. It made a 7.19% EPRA NAV total return for the period from the IPO to 31 December 2017, compared to 10.79% for the EPRA/ NAREIT UK REITs Index. The NAV was 100.65p per share as at […]
International Public Partnership says Carillion hit was just £1.5m – International Public Partnership has released results for the year ended 31 December 2017. Highlights are: Net Asset Value (‘NAV’) growth to GBP2.0 billion (2016: GBP1.6 billion) translates into NAV per share growth to 145.0 pence (2016: 142.2 pence). They say that this reflects steady progression […]
